William Kim, MD, and Tracy Rose, MD, MPH, published a review highlighting new scientific insights that have led to advances in kidney cancer treatment and increased survival rates.
Jonathan Serody, MD, Ian Davis, MD, PhD, and colleagues report ILC2s can change functions after a patient receives stem cells, thereby preventing a healthy rebuilding of the immune system.
The San Antonio Breast Cancer Symposium features presentations outlining basic, translational, clinical and community-based study findings focused on advancing the prevention, diagnosis and treatment of breast cancer.
Researchers have learned more about an enzyme found to be overly expressed in patients with hereditary breast cancer, ovarian cancer and prostate cancer.
Twelve UNC Lineberger Comprehensive Cancer Center members were named to Clarivate’s 2023 Highly Cited Researchers™ list, which recognized scientists who published papers that ranked in the top 1% of cited publications in their field between 2012-2022.
The AACR has elected Charles Perou, PhD, as a fellow to the AACR Academy. Members of this year’s class will be formally recognized at the AACR’s annual meeting.
UNC Lineberger faculty and trainees will be presenting their research findings and sharing their insights at education sessions during the American Association for Cancer Research’s annual meeting April 14-19.
The UNC School of Medicine Office of Graduate Education presented mentorship awards to four UNC Lineberger members, Jessica Bowser, PhD, Sharon Campbell, PhD, Charles Perou, PhD, and Will Valdar, PhD.
UNC Lineberger’s Ian Davis, MD, PhD, was awarded $1 million by the The V Foundation to support his work to improve CAR-T therapy for pediatric solid tumors.
A multi-institutional national study has identified unique molecular features responsible for the development and progression of metastatic breast cancer.
A genomic study of more than 200 people with the most common type of bladder cancer that has spread could help guide how the cancer would respond to immunotherapy.